论文部分内容阅读
目的：探讨人重组γ－干扰素（ｈｒＩＦＮ－γ）经雾化吸入后对哮喘患者气道高反应性（ＢＨＲ）的影响，试图寻找治疗哮喘的新途径。方法：选择１４例过敏性哮喘患者，每天吸入ｈｒＩＦＮ－γ１．０×１０６单位，并以吸入安慰剂（生理盐水）的１０例患者做对照，分别于吸入前、吸入后第７天和第１４天测定其气道反应性和肺功能。结果：ｈｒＩＦＮ－γ吸入组于治疗后第７天及第１４天其ＰＣ２０－ＦＥＶ１值均较治疗前有明显提高（Ｐ＜０．０１），而安慰剂组治疗前后ＰＣ２０－ＦＥＶ１值无变化。两组治疗前后肺功能无明显改变。结论：吸入ｈｒＩＦＮ－γ可使过敏性哮喘患者的ＢＨＲ降低，在哮喘治疗上有一定应用价值
Objective: To investigate the effect of inhaled human interferon gamma (IFN-γ) on airway hyperresponsiveness (BHR) in patients with asthma after inhalation, and to find a new way to treat asthma. Methods: Fourteen patients with allergic asthma were enrolled, and inhaled hrIFN-γ1.0 × 106 units per day. Ten patients undergoing inhalation of placebo (saline) were compared before inhalation, 7 days after inhalation and 14 Day to determine its airway responsiveness and lung function. Results: The values of PC20-FEV1 in hrIFN-γ inhalation group on day 7 and day 14 after treatment were significantly higher than those before treatment (P <0.01), while those in placebo group did not change before and after treatment. Before and after treatment, no significant changes in lung function. Conclusion: Inhaled hrIFN-γ can reduce the BHR in patients with allergic asthma, which has some value in the treatment of asthma